Actively Recruiting
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Led by Janssen Research & Development, LLC · Updated on 2026-05-04
355
Participants Needed
13
Research Sites
243 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with standard of care (SOC) lutetium Lu-177 vipivotide tetraxetan. Part 4 of this study further evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with JNJ-101556143 in participants with advanced prostate cancer.
CONDITIONS
Official Title
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed adenocarcinoma of the prostate, including adenocarcinoma with small cell or neuroendocrine features, excluding small cell carcinoma, carcinoid tumor, mixed neuroendocrine carcinoma, or large cell neuroendocrine carcinoma
- Measurable or evaluable disease according to PCWG3 criteria
- Prior orchiectomy or ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analog before and during the treatment phase (for Parts 1, 2A, 2B, 3, and 4)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You will not qualify if you...
- History of autoimmune disease within 12 months before signing consent
- Any of the following within 6 months before signing consent: myocardial infarction, severe or unstable angina, significant ventricular arrhythmias, congestive heart failure (New York Heart Association class II to IV), transient ischemic attack, or cerebrovascular accident
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States, 80045
Actively Recruiting
2
University Of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
3
START New Jersey
East Brunswick, New Jersey, United States, 08816
Actively Recruiting
4
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
New York, New York, United States, 10032
Actively Recruiting
5
Oregon Health And Science University
Portland, Oregon, United States, 97239
Actively Recruiting
6
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
7
Tennessee Oncology
Nashville, Tennessee, United States, 37203
Actively Recruiting
8
South Texas Accelerated Research Therapeutics, LLC (START)
San Antonio, Texas, United States, 78229
Actively Recruiting
9
Swedish Medical Center
Seattle, Washington, United States, 98104
Actively Recruiting
10
Institut Bergonie
Bordeaux, France, 33000
Actively Recruiting
11
Centre Leon Berard
Lyon, France, 69008
Actively Recruiting
12
Institut Gustave Roussy
Villejuif, France, 94800
Actively Recruiting
13
The Cancer Institute Hospital of JFCR
Tokyo, Japan, 135 8550
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here